Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model

Schwander B, Gradl B, Zoellner Y, Lindgren P, Diener H-C, Lueders S, Schrader J, Antonanzas Villar F, Greiner W, Jonsson B (2009)
VALUE IN HEALTH 12(6): 857-871.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
DOI
Autor*in
Schwander, Bjoern; Gradl, Birgit; Zoellner, York; Lindgren, Peter; Diener, Hans-Christoph; Lueders, Stephan; Schrader, Joachim; Antonanzas Villar, Fernando; Greiner, WolfgangUniBi; Jonsson, Bengt
Einrichtung
Fakultät für Gesundheitswissenschaften
Abstract / Bemerkung
Objective: To investigate the cost-utility of eprosartan versus enalapril (primary prevention) and versus nitrendipine (secondary prevention) on the basis of head-to-head evidence from randomized controlled trials. Methods: The HEALTH model (Health Economic Assessment of Life with Teveten((R)) for Hypertension) is an object-oriented probabilistic Monte Carlo simulation model. It combines a Framingham-based risk calculation with a systolic blood pressure approach to estimate the relative risk reduction of cardiovascular and cerebrovascular events based on recent meta-analyses. In secondary prevention, an additional risk reduction is modeled for eprosartan according to the results of the MOSES study ("Morbidity and Mortality after Stroke-Eprosartan Compared to Nitrendipine for Secondary Prevention"). Costs and utilities were derived from published estimates considering European country-specific health-care payer perspectives. Results: Comparing eprosartan to enalapril in a primary prevention setting the mean costs per quality adjusted life year (QALY) gained were highest in Germany (24,036) followed by Belgium (17,863), the UK (16,364), Norway ( 13,834), Sweden ( 11,691) and Spain ( 7918). In a secondary prevention setting (eprosartan vs. nitrendipine) the highest costs per QALY gained have been observed in Germany (9136) followed by the UK (6008), Norway (1695), Sweden (907), Spain (-2054) and Belgium (-5767). Conclusions: Considering a 30,000 willingness-to-pay threshold per QALY gained, eprosartan is cost-effective as compared to enalapril in primary prevention (patients >= 50 years old and a systolic blood pressure >= 160 mm Hg) and cost-effective as compared to nitrendipine in secondary prevention (all investigated patients).
Stichworte
cost-utility; enalapril; nitrendipine; eprosartan
Erscheinungsjahr
2009
Zeitschriftentitel
VALUE IN HEALTH
Band
12
Ausgabe
6
Seite(n)
857-871
ISSN
1098-3015
Page URI
https://pub.uni-bielefeld.de/record/1591464

Zitieren

Schwander B, Gradl B, Zoellner Y, et al. Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model. VALUE IN HEALTH. 2009;12(6):857-871.
Schwander, B., Gradl, B., Zoellner, Y., Lindgren, P., Diener, H. - C., Lueders, S., Schrader, J., et al. (2009). Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model. VALUE IN HEALTH, 12(6), 857-871. https://doi.org/10.1111/j.1524-4733.2009.00507.x
Schwander, Bjoern, Gradl, Birgit, Zoellner, York, Lindgren, Peter, Diener, Hans-Christoph, Lueders, Stephan, Schrader, Joachim, Antonanzas Villar, Fernando, Greiner, Wolfgang, and Jonsson, Bengt. 2009. “Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model”. VALUE IN HEALTH 12 (6): 857-871.
Schwander, B., Gradl, B., Zoellner, Y., Lindgren, P., Diener, H. - C., Lueders, S., Schrader, J., Antonanzas Villar, F., Greiner, W., and Jonsson, B. (2009). Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model. VALUE IN HEALTH 12, 857-871.
Schwander, B., et al., 2009. Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model. VALUE IN HEALTH, 12(6), p 857-871.
B. Schwander, et al., “Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model”, VALUE IN HEALTH, vol. 12, 2009, pp. 857-871.
Schwander, B., Gradl, B., Zoellner, Y., Lindgren, P., Diener, H.-C., Lueders, S., Schrader, J., Antonanzas Villar, F., Greiner, W., Jonsson, B.: Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model. VALUE IN HEALTH. 12, 857-871 (2009).
Schwander, Bjoern, Gradl, Birgit, Zoellner, York, Lindgren, Peter, Diener, Hans-Christoph, Lueders, Stephan, Schrader, Joachim, Antonanzas Villar, Fernando, Greiner, Wolfgang, and Jonsson, Bengt. “Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model”. VALUE IN HEALTH 12.6 (2009): 857-871.

11 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysis.
Sanchez-Santos R, Padin EM, Adam D, Borisenko O, Fernandez SE, Dacosta EC, Fernández SG, Vazquez JT, de Adana JCR, de la Cruz Vigo F., Expert Rev Pharmacoecon Outcomes Res 18(3), 2018
PMID: 29188745
The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m2.
Dilla T, Alexiou D, Chatzitheofilou I, Ayyub R, Lowin J, Norrbacka K., J Med Econ 20(5), 2017
PMID: 28008768
Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.
Verhoef TI, Redekop WK, Langenskiold S, Kamali F, Wadelius M, Burnside G, Maitland-van der Zee AH, Hughes DA, Pirmohamed M., Pharmacogenomics J 16(5), 2016
PMID: 27272045
A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO).
Taylor M, Serbetci E, Ferreira A, Gairy K, Lewis L, Blouin J, Mitchell P., J Med Econ 17(6), 2014
PMID: 24673384
Health related quality of life in coronary patients and its association with their cardiovascular risk profile: results from the EUROASPIRE III survey.
De Smedt D, Clays E, Annemans L, Doyle F, Kotseva K, Pająk A, Prugger C, Jennings C, Wood D, De Bacquer D., Int J Cardiol 168(2), 2013
PMID: 23201081
A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden.
Fredrikson S, McLeod E, Henry N, Pitcher A, Lowin J, Cuche M, Fajutrao L, Perard R, Bates D, Chan A., J Med Econ 16(6), 2013
PMID: 23556422
A cost-utility analysis of hypertension treatment in Greece: assessing the impact of age, sex and smoking status, on outcomes.
Athanasakis K, Souliotis K, Tountas Y, Kyriopoulos J, Hatzakis A., J Hypertens 30(1), 2012
PMID: 22157591
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization.
Crowley MJ, Powers BJ, Myers ER, McBroom AJ, Sanders GD., Am Heart J 163(5), 2012
PMID: 22607854
Cost of clinical events in health economic evaluations in Germany: a systematic review.
Scheuringer M, Sahakyan N, Krobot KJ, Ulrich V., Cost Eff Resour Alloc 10(1), 2012
PMID: 22651885
Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.
De Smedt D, Kotseva K, De Bacquer D, Wood D, De Backer G, Dallongeville J, Seppo L, Pajak A, Reiner Z, Vanuzzo D, Georgiev B, Gotcheva N, Annemans L., Eur Heart J 33(22), 2012
PMID: 22843446
Eprosartan: a review of its use in hypertension.
Plosker GL., Drugs 69(17), 2009
PMID: 19911859

114 References

Daten bereitgestellt von Europe PubMed Central.


Elliott, 2002
2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A; European Society of Hypertension; European Society of Cardiology., Blood Press. 16(3), 2007
PMID: 17846925
Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials.
Pearce KA, Furberg CD, Rushing J., Arch Fam Med 4(11), 1995
PMID: 7582060
Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators.
Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Perry M, Prineas R, Schron E., Ann. Intern. Med. 126(10), 1997
PMID: 9148648
Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis.
Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD., JAMA 277(9), 1997
PMID: 9042847
Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review.
Rashid P, Leonardi-Bee J, Bath P., Stroke 34(11), 2003
PMID: 14576382
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.
Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration., Lancet 362(9395), 2003
PMID: 14615107
Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension.
Cheung BM, Cheung GT, Lauder IJ, Lau CP, Kumana CR., J Hum Hypertens 20(1), 2006
PMID: 16121197
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS., JAMA 289(19), 2003
PMID: 12759325
Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group.
Sega R., Blood Press. 8(2), 1999
PMID: 10451039
Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.
Staessen JA, Wang JG, Thijs L., J. Hypertens. 21(6), 2003
PMID: 12777939
Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials.
Wang JG, Staessen J., J Clin Hypertens (Greenwich) 5(1), 2003
PMID: 12556657
Blood pressure and cardiovascular disease in the Asia Pacific region.
Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S; Asia Pacific Cohort Studies Collaboration., J. Hypertens. 21(4), 2003
PMID: 12658016
Blood pressure and stroke: an overview of published reviews.
Lawes CM, Bennett DA, Feigin VL, Rodgers A., Stroke 35(3), 2004
PMID: 14976329
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.
PROGRESS Collaborative Group., Lancet 358(9287), 2001
PMID: 11589932
Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group., Stroke 36(6), 2005
PMID: 15879332
Mechanisms for the clinical benefits of angiotensin II receptor blockers.
Schmieder RE., Am. J. Hypertens. 18(5 Pt 1), 2005
PMID: 15882557
Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method.
Hunink MG, Bult JR, de Vries J, Weinstein MC., Med Decis Making 18(3), 1998
PMID: 9679999
Primary and subsequent coronary risk appraisal: new results from the Framingham study.
D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, Hartz SC., Am. Heart J. 139(2 Pt 1), 2000
PMID: 10650300
Probability of stroke: a risk profile from the Framingham Study.
Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB., Stroke 22(3), 1991
PMID: 2003301
Survival and recurrence following stroke. The Framingham study.
Sacco RL, Wolf PA, Kannel WB, McNamara PM., Stroke 13(3), 1982
PMID: 7080120
Survival following initial cardiovascular events—The Framingham Study Section 35
Cupples, 1988

World, 0
Ten-year survival after first-ever stroke in the perth community stroke study.
Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C., Stroke 34(8), 2003
PMID: 12843343
Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study.
Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU., Stroke 32(12), 2001
PMID: 11739965
Good parameters and implementations for combined multiple recursive random number generators
L'Ecuyer, Oper Res 47(), 1999
Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes.
Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ., Clin Ther 23(12), 2001
PMID: 11813934
Compliance with secondary prevention of ischemic stroke: a prospective evaluation.
Sappok T, Faulstich A, Stuckert E, Kruck H, Marx P, Koennecke HC., Stroke 32(8), 2001
PMID: 11486121
Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium.
Annemans L, Crott R, Degraeve D, Dubois D, Huybrechts M, Peys F, Robays H, Smets J, Tomas M, Vanschoubroek K; Pharmaco-Economic Committee PEC of the Belgian Society for pharmacoepidemiology., Pharm World Sci 24(1), 2002
PMID: 11980170
German recommendations on health economic evaluation—third and updated version of the Hanover Consensus
Schulenburg, Gesundheitsökon Qualitätsmanage 12(), 2007

Department, 0
Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation.
Rovira J, Antonanzas F., Pharmacoeconomics 8(3), 1995
PMID: 10155620

Swedish, 0

National, 0
Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal.
Evans C, Tavakoli M, Crawford B., Health Care Manag Sci 7(1), 2004
PMID: 14977093

Socialstyrelsen, 0
Hälso-och sjukvården behöver kunskap om hur befolkningen värderar hälsan
Persson, Läkartidningen 100(), 2003
Kostnadseffektivitet som kriterium för subvention av läkemedel—en bra idé?
Lundin, ekonomiskdebatt 34(), 2004

Bastian, 2005
[The 1998 Federal Health Survey. Experiences, results, perspectives]
Bellach BM., Gesundheitswesen 61 Spec No(), 1999
PMID: 10726396
Microalbuminuria in diabetic and hypertensive patients and the general population--consequences of various diagnostic criteria--the Nord-Trondelag Health Study (HUNT).
Hallan H, Romundstad S, Kvenild K, Holmen J., Scand. J. Urol. Nephrol. 37(2), 2003
PMID: 12745725
Microalbuminuria in treated hypertensives: only a mirror image of cardiovascular risk? The HUNT Study, Norway.
Kvenild K, Romundstad S, Midthjell K, Kruger O, Hallan H, Holmen J., Scand J Prim Health Care 24(3), 2006
PMID: 16923623
[Distribution, determinants and reference values of left ventricular parameters in the general population--results of the MONICA/KORA echocardiography studies].
Kuch B, Schunkert H, Muscholl M, Doring A, von Scheidt W, Hense HW; MONICA/KORA-Studiengruppe., Gesundheitswesen 67 Suppl 1(), 2005
PMID: 16032520
Blood pressure and other cardiovascular risk factors among treated hypertensives in Swedish primary health care.
Cederholm J, Nilsson PM, Anderberg CP, Froberg L, Petersson U; Q-Heart Study Group., Scand J Prim Health Care 20(4), 2002
PMID: 12564574
Control of blood pressure and risk of first acute myocardial infarction: Skaraborg hypertension project.
Lindblad U, Rastam L, Ryden L, Ranstam J, Isacsson SO, Berglund G., BMJ 308(6930), 1994
PMID: 8142790
Cardiovascular risk factors in treated hypertensives--a nation-wide, cross-sectional study in Sweden.
Nilsson P, Andersson DK, Andersson PE, Schwan A, Ostlind B, Malmborg R, Lithell H, Andersson OK., J. Intern. Med. 233(3), 1993
PMID: 8450292
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.
Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC., Eur. Heart J. 27(8), 2006
PMID: 16527828
Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community.
Ostgren CJ, Merlo J, Rastam L, Lindblad U., Diabetes Obes Metab 6(5), 2004
PMID: 15287930
International variability of ages at menarche and menopause: patterns and main determinants.
Thomas F, Renaud F, Benefice E, de Meeus T, Guegan JF., Hum. Biol. 73(2), 2001
PMID: 11446429
Age at natural menopause and stroke mortality: cohort study with 3561 stroke deaths during 37-year follow-up.
Jacobsen BK, Heuch I, Kvale G., Stroke 35(7), 2004
PMID: 15178828
Socio-demographic and psychosocial factors are associated with features of the metabolic syndrome. The Women's Health in the Lund Area (WHILA) study.
Lidfeldt J, Nyberg P, Nerbrand C, Samsioe G, Schersten B, Agardh CD., Diabetes Obes Metab 5(2), 2003
PMID: 12630935
[Risk assessment for a first stroke in Spanish hypertensive population in primary care. The ERIC-HTA study].
Lozano JV, Redon J, Cea-Calvo L, Fernandez-Perez C, Navarro J, Bonet A, Gonzalez-Esteban J; Investigadores del Estudio ERIC-HTA 2003., Med Clin (Barc) 125(7), 2005
PMID: 16137484
Risk factor clustering in patients with hypertension and non-insulin-dependent diabetes mellitus. The Skaraborg Hypertension Project.
Bog-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A, Rastam L., J. Intern. Med. 243(3), 1998
PMID: 9627160

AUTHOR UNKNOWN, 0
Survival in patients with type 2 diabetes in a Swedish community: skaraborg hypertension and diabetes project.
Ostgren CJ, Lindblad U, Melander A, Rastam L., Diabetes Care 25(8), 2002
PMID: 12145224
[Risk factors related to osteoporosis and age of onset of menopause in the general population].
Ceinos Arcones M, Acosta Estevez E, Martin Perpinan C, Yeves Yeves L, Atienza Lopez JM, Gonzalez Galan MA., Aten Primaria 24(3), 1999
PMID: 10444867
Evidence for a secular trend in menopausal age: a population study of women in Gothenburg.
Rodstrom K, Bengtsson C, Milsom I, Lissner L, Sundh V, Bjourkelund C., Menopause 10(6), 2003
PMID: 14627863
[Factors associated the control of hypertension among older Spaniards, over 60 years of age].
Tuesca-Molina R, Guallar-Castillon P, Banegas-Banegas JR, Graciani-Perez Regadera A., Rev. Esp. Salud Publica 80(3), 2006
PMID: 16838468
International variability of ages at menarche and menopause: patterns and main determinants.
Thomas F, Renaud F, Benefice E, de Meeus T, Guegan JF., Hum. Biol. 73(2), 2001
PMID: 11446429
Health-related quality of life by disease and socio-economic group in the general population in Sweden.
Burstrom K, Johannesson M, Diderichsen F., Health Policy 55(1), 2001
PMID: 11137188
An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses.
Bell CM, Chapman RH, Stone PW, Sandberg EA, Neumann PJ., Med Decis Making 21(4), 2001
PMID: 11475385

FPS, 0

Federal, 0

Statistics, 0

The, 0

Statistics, 0

The, 0
[Cost-estimates for stroke].
Fjaertoft H, Indredavik B., Tidsskr. Nor. Laegeforen. 127(6), 2007
PMID: 17363987

The, 0

Institut, 0

Rote, 0

Norwegian, 0

IMS, 0

Pharmaceutical, 0

National, 0
Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial.
Staessen JA, Den Hond E, Celis H, Fagard R, Keary L, Vandenhoven G, O'Brien ET; Treatment of Hypertension Based on Home or Office Blood Pressure (THOP) Trial Investigators., JAMA 291(8), 2004
PMID: 14982911

Association, 0
Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension.
Johannesson M, Meltzer D, O'Conor RM., Med Decis Making 17(4), 1997
PMID: 9343796
[Short-and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain].
Badia X, Bueno H, Gonzalez Juanatey JR, Valentin V, Rubio M., Rev Esp Cardiol 58(12), 2005
PMID: 16371197

UK, 0
The comparative medical costs of atherothrombotic disease in European countries.
Levy E, Gabriel S, Dinet J., Pharmacoeconomics 21(9), 2003
PMID: 12807366
Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.
Muls E, Van Ganse E, Closon MC., Atherosclerosis 137 Suppl(), 1998
PMID: 9694550
Cost estimates of brain disorders in Belgium.
Schoenen J, Gianni F, Schretlen L, Sobocki P., Acta Neurol Belg 106(4), 2006
PMID: 17323838
Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project.
Kolominsky-Rabas PL, Heuschmann PU, Marschall D, Emmert M, Baltzer N, Neundorfer B, Schoffski O, Krobot KJ., Stroke 37(5), 2006
PMID: 16574918
Comparisons of hypertension-related costs from multinational clinical studies.
Mullins CD, Sikirica M, Seneviratne V, Ahn J, Akhras KS., Pharmacoeconomics 22(15), 2004
PMID: 15449964
Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.
Ray JA, Valentine WJ, Secnik K, Oglesby AK, Cordony A, Gordois A, Davey P, Palmer AJ., Curr Med Res Opin 21(10), 2005
PMID: 16238902
Medical resource use and costs of health care after acute stroke in Germany.
Rossnagel K, Nolte CH, Muller-Nordhorn J, Jungehulsing GJ, Selim D, Bruggenjurgen B, Villringer A, Willich SN., Eur. J. Neurol. 12(11), 2005
PMID: 16241975
[Direct cost of cerebrovascular disease during the first year of follow-up]
Carod-Artal FJ, Egido-Navarro JA, Gonzalez-Gutierrez JL, Varela de Seijas E., Rev Neurol 28(12), 1999
PMID: 10478369
Health care and social welfare costs in home-based and hospital-based rehabilitation after stroke.
Andersson A, Levin LA, Oberg B, Mansson L., Scand J Caring Sci 16(4), 2002
PMID: 12445108
Cost of stroke in Sweden: an incidence estimate.
Ghatnekar O, Persson U, Glader EL, Terent A., Int J Technol Assess Health Care 20(3), 2004
PMID: 15446769
Stroke treatment economic model (STEM): predicting long-term costs from functional status.
Caro JJ, Huybrechts KF., Stroke 30(12), 1999
PMID: 10582980
The economic burden of stroke in the United Kingdom
Youman, Pharmacoeconomics 21(Suppl. 1), 2003
Costs of coronary heart disease and stroke: the case of Sweden.
Zethraeus N, Molin T, Henriksson P, Jonsson B., J. Intern. Med. 246(2), 1999
PMID: 10447784
The hospital cost of vertebral fractures in the EU: estimates using national datasets.
Finnern HW, Sykes DP., Osteoporos Int 14(5), 2003
PMID: 12730759

Balestat, 2006
Resource utilization and costs of stroke unit care in Germany.
Dodel RC, Haacke C, Zamzow K, Paweilik S, Spottke A, Rethfeldt M, Siebert U, Oertel WH, Schoffski O, Back T., Value Health 7(2), 2004
PMID: 15164804

Institut, 0

Norwegian, 0

AUTHOR UNKNOWN, 0

Swedish, 0

Stockholm, 0

Allender, 2007
Evaluation of the costs of coronary heart disease in Belgium
Annemans, Value Health 1(), 1998
[Costs of coronary heart diseases over the remaining life time in coronary heart disease cases--an analysis of the current status of coronary heart disease cases in Germany from the social perspective]
Klever-Deichert G, Hinzpeter B, Hunsche E, Lauterbach KW., Z Kardiol 88(12), 1999
PMID: 10654390
Acute coronary syndromes in Europe: 1-year costs and outcomes.
Taylor MJ, Scuffham PA, McCollam PL, Newby DE., Curr Med Res Opin 23(3), 2007
PMID: 17355731
The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).
Clarke P, Gray A, Legood R, Briggs A, Holman R., Diabet. Med. 20(6), 2003
PMID: 12786677
[Heterogeneity of costs of diabetic patients: the Cost of Diabetes Mellitus Study]
Koster I, Hauner H, von Ferber L., Dtsch. Med. Wochenschr. 131(15), 2006
PMID: 16607599
A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
Gomez-Gerique JA, Casciano R, Stern L, Rejas J., Eur J Health Econ 5(3), 2004
PMID: 15714350
Measurement of health outcome and associated costs in cardiovascular disease.
Jonsson B., Eur. Heart J. 17 Suppl A(), 1996
PMID: 8737194
Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B., Curr Med Res Opin 17(1), 2001
PMID: 11464450
Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
Neutel JM., Curr Med Res Opin 24(8), 2008
PMID: 18616863
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R., Clin Ther 29(4), 2007
PMID: 17617280
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators., Lancet 372(9638), 2008
PMID: 18707986

National, 2006
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 19508663
PubMed | Europe PMC

Suchen in

Google Scholar